Antiretrovirals

For more information, visit the Antiretrovirals Page of the HIV/AIDS Unit of the Pan American Health Organization.

   Technical Documents


Technical Documents

PAHO Policy in the Procurement of Pharmaceutical Products for Projects Financed by the GFATM
The following policy has been elaborated by PAHO in support of Principal Recipients designated by the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria (GFATM) that wish to use the procurement services of PAHO for the purchase of pharmaceutical products required in the implementation of projects financed by the GFATM.(15/Dec/2003)
In English       PDF(50.43k)  
en español     PDF(56.52k)  

Reagent Prices Established in the Negotiations of the 10 Latin American Countries (June 2003)
The prices of the reagents used in HIV/AIDS care in the list below were obtained after negotiations between the Ministers of Health of the participating countries and the companies that manufacture these reagents. (31/Aug/2003)
In English       PDF(75.6k)  
en español     PDF(25.06k)  

Fact Sheet: Antiretroviral price negotiation in 10 Latin American countries
In Latin America and the Caribbean, subregional negotiations for the expansion of access to antiretrovirals took place in the Caribbean (June, 2002), Central America (January, 2003) and within a group of 10 Latin American countries (Peru, Bolivia, Colombia, Ecuador, Venezuela, Chile, Argentina, Mexico, Paraguay and Uruguay) in June of 2003.This document contains a summary of the results of the negotiation of the group of 10 Latin American countries.(31/Aug/2003)
In English       WORDL(91.14k)   PDF(74.24k)  
en español     WORDL(103.94k)   PDF(27.68k)  

Elements of effective antiretroviral procurement
This document contains elements for an effective policy of antiretroviral purchases. Through the use of effective methods of purchases Latin America and the Caribbean countries can take advantage of more cost-effective pharmaceutical products, in the correct quantities and quality, in a timely manner and at the lowest possible cost.(30/Aug/2003)
In English       PDF(108.71k)  
en español     PDF(26.18k)  

Tools to determine quality of antiretrovirals
Before deciding to buy antiretroviral drugs, countries should establish an internal process in order to determine the criteria and references for acceptable quality. This document contains several international quality references whose application, combined with the public health authorities own regulatory systems, constitute an effective framework in which the quality of the product can be assured.(30/Aug/2003)
In English       WORDL(90.62k)   PDF(47.12k)  
en español     WORDL(100.86k)   PDF(23.21k)  

Legislation and milestones in access to antiretroviral treatment in Latin America and the Caribbean
This document contains the milestones and legislations of various countries of Latin America and the Caribbean that have been relevant in the effort to expand the access to antiretroviral treatment. This information has been obtained from the Subregional Framework Documents, which served as basis for the subregional price negotiations.(2/Aug/2003)
In English       PDF(108.73k)  
en español     PDF(44.51k)  

Negociación de la subregión Centroamericana – Comunicado de prensa de la COMISCA
Negociaciones realizadas entre los gobiernos de Centroamérica y cinco compañías farmacéuticas condujeron a una reducción histórica en los precios de los antirretrovirales, medicamentos usados contra el VIH/SIDA. El tratamiento más común en la subregión (AZT+3TC+EFV) costará entre US$ 1.035 y US$ 1.454 al año. Esto representa una reducción promedio del 55% frente a los precios actuales en Centroamérica para medicamentos de marca.(31/Jul/2003)
en español     WORDL(46.08k)  

Position of REDLA+ on procurement generic and copied versions of antiretroviral medications
This document contains the position of the L atin American Network of People Living with HIV/AIDS (REDLA+) regarding the purchase and distribution of generic or copies of antiretroviral drugs for the treatment of HIV/AIDS.(30/Jun/2003)
In English       WORDL(51.71k)   PDF(139.34k)  
en español     WORDL(55.3k)   PDF(34k)  

Results of the subregional price negotiations in Latin America and the Caribbean
In Latin America and the Caribbean, subregional negotiations for the expansion of access to antiretrovirals took place in the Caribbean (June, 2002), Central America (January, 2003) and within a group of 10 Latin American countries (Peru, Bolivia, Colombia, Ecuador, Venezuela, Chile, Argentina, Mexico, Paraguay and Uruguay) in June of 2003. This document contains a summary of the results of these negotiations.(30/Jun/2003)
In English       WORDL(94.72k)   PDF(54.46k)  
en español     WORDL(99.33k)   PDF(23.05k)  

Fact Sheet: Antiretroviral price negotiation in the Caribbean
In Latin America and the Caribbean, subregional negotiations for the expansion of access to antiretrovirals took place in the Caribbean (June, 2002), Central America (January, 2003) and within a group of 10 Latin American countries (Peru, Bolivia, Colombia, Ecuador, Venezuela, Chile, Argentina, Mexico, Paraguay and Uruguay) in June of 2003. This document contains a summary of the results of the Caribbean negotiation.(30/Jun/2003)
In English       WORDL(89.6k)   PDF(69.87k)  
en español     WORDL(100.86k)   PDF(27.62k)  

Framework document: Process of joint negotiation for the access to antiretroviral and reactive drugs in the Andean subregion, Argentina Mexico and Paraguay (available in Spanish)
In Latin America and the Caribbean, subregional negotiations for the expansion of access to antiretrovirals took place in the Caribbean (June, 2002), Central America (January, 2003) and within a group of 10 Latin American countries (Peru, Bolivia, Colombia, Ecuador, Venezuela, Chile, Argentina, Mexico, Paraguay and Uruguay) in June of 2003.This document contains an analysis of epidemiological situation and of the state of the access to antiretrovirals of the group of 10 Latin American countries and was used as a framework document for the negotiation of these countries. (Available in Spanish)(30/Jun/2003)
en español     PDF(180.2k)  

VIH y Comunicación: las estrategias de los Programas Nacionales de SIDA de América Latina
El propósito de la reunión fué examinar cómo los Programas Nacionales de VIH/SIDA de América Latina elaboran sus estrategias de comunicación, con énfasis en la planificación, la evaluación, el trabajo interinstitucional, el financiamiento y otros temas (16/Jun/2003)
en español     HTML(5.57k)  

Antiretroviral prices agreed in the negotiations of the 10 Latin American countries (June 2003)
The prices of the antiretroviral drugs in the list below were obtained after negotiations between the Ministers of Health of the participating countries and the pharmaceutical companies that manufacture these drugs. In addition to the prices set, the list includes the names of the laboratories that participated in each of the negotiations, the products that were the object of the negotiations (with the brand name and the generic name for companies that manufacture original products, or the designation “generic” for companies that produce generics), the dose in milligrams, and the dosage form of the unit negotiated. (1/Jun/2003)
In English       PDF(73.19k)  
en español     PDF(30.95k)  

Antiretroviral prices agreed in the Central American negotiations (January 2003)
In Latin America and the Caribbean, subregional negotiations for the expansion of access to antiretrovirals took place in the Caribbean (June, 2002), Central America (January, 2003) and within a group of 10 Latin American countries (Peru, Bolivia, Colombia, Ecuador, Venezuela, Chile, Argentina, Mexico, Paraguay and Uruguay) in June of 2003.This document contains a summary of the results of the Central American negotiations.(31/Jan/2003)
In English       PDF(89.08k)  
en español     PDF(24.76k)  

Framework document for the Central American region: Foundations for the Accelerated Access Initiative
In Latin America and the Caribbean, subregional negotiations for the expansion of access to antiretrovirals took place in the Caribbean (June, 2002), Central America (January, 2003) and within a group of 10 Latin American countries (Peru, Bolivia, Colombia, Ecuador, Venezuela, Chile, Argentina, Mexico, Paraguay and Uruguay) in June of 2003.This document contains an analysis of epidemiological situation and of the state of the access to antiretrovirals in Central America and was used as a framework document for the negotiation of that subregion.(31/Jan/2003)
In English       PDF(356.06k)  
en español     PDF(165.31k)  

Características técnicas y condiciones de transporte y conservación de la carga viral y CD4
Características técnicas y condiciones de transporte y conservación de la carga viral y CD4(24/Oct/2002)
en español     PDF(96.77k)  

Framework for the Accelerating Initiative of Access in the Caribbean
In Latin America and the Caribbean, subregional negotiations for the expansion of access to antiretrovirals took place in the Caribbean (June, 2002), Central America (January, 2003) and within a group of 10 Latin American countries (Peru, Bolivia, Colombia, Ecuador, Venezuela, Chile, Argentina, Mexico, Paraguay and Uruguay) in June of 2003.This document contains an analysis of epidemiological situation and of the state of the access to antiretrovirals in the Caribbean and was used as a framework document for the negotiation of that subregion.(30/Jul/2002)
In English       WORDL(413.7k)  
en español     WORDL(439.81k)   PDF(197.68k)  

Antiretroviral prices agreed in the Caribbean negotiations (July 2002)
The prices of the antiretroviral drugs in the list below were obtained after negotiations between the Ministers of Health of the participating countries and the pharmaceutical companies that manufacture these drugs. In addition to the prices set, the list includes the names of the laboratories that participated in each of the negotiations, the products that were the object of the negotiations (with the brand name and the generic name for companies that manufacture original products, or the designation “generic” for companies that produce generics), the dose in milligrams, and the dosage form of the unit negotiated. (30/Jun/2002)
In English       WORDL(101.38k)   PDF(85.68k)  
en español     WORDL(118.27k)   PDF(19.74k)